Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the sale, the chief operating officer now owns 205,695 shares of the company’s stock, valued at $17,735,022.90. The trade was a 3.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jim Wassil also recently made the following trade(s):

• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total value of $669,280.00.
• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.49, for a total value of $739,920.00.

Vaxcyte Trading Down 0.4 %

Vaxcyte stock opened at $89.01 on Friday. The stock has a market cap of $11.09 billion, a P/E ratio of -19.35 and a beta of 0.98. The stock has a 50 day moving average of $87.27 and a 200-day moving average of $94.42. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the firm earned ($0.91) EPS. As a group, equities analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $145.71.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently made changes to their positions in the business. Riverview Trust Co acquired a new stake in shares of Vaxcyte during the 3rd quarter valued at approximately $27,000. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the 4th quarter valued at approximately $28,000. Blue Trust Inc. raised its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares in the last quarter. Finally, Meeder Asset Management Inc. raised its position in shares of Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.